Business Information
The group's principal activity is to develop proprietary technologies for the synthesis and manufacture of complex carbohydrates. Through its proprietary enzymatic technology platform, the group enables the production and manipulation of complex carbohydrates either as stand-alone carbohydrate molecules or as carbohydrate structures attached to recombinant therapeutic glycoproteins and glycolipids. It uses its technology in its glycoadvance program to complete the human carbohydrate structures on therapeutic glycoprotein; glycotherapeutics program to develop carbohydrate-based therapeutics; and glycoactives program to develop carbohydrate-based food and nutritional ingredients. The group has commercial and collaborative agreements with wyeth pharmaceuticals, neuronyx, inc and progenics pharmaceuticals, inc. The group is in development stage.
|
Name |
Title
|
Email
|
Patrick Gage | Chmn. | N/A | Brian Davis | Sr. VP, CFO | N/A | Bruce Wallin | VP - Clinical Development, Chief Medical Officer | N/A | David Zopf | Chief Scientific Officer, Exec. VP | N/A | Debra Poul | Sr. VP, General Counsel, Sec. | N/A |
|
Year |
Sales |
Net Income |
2006 | 6,184 | (27,107) | 2005 | 6,137 | (51,839) | 2004 | 5,070 | (41,642)
| |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
Click for more Executives |
|
|